ASX RELEASE 11 November 2026 First Sale of iTrack™ Advance in South Korea Highlights • First commercial sale of iTrack™ Advance made in South Korea during the first week of November 2026. • Follows regulatory clearance from the Ministry of Food and Drug Safety (MFDS) in mid-2025 and...
First Sale iTrack Advance in South Korea
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Nova Eye Medical Ltd has announced its first commercial sale of iTrack™ Advance in South Korea, marking a significant milestone for the company. This sale follows regulatory clearance from the Ministry of Food and Drug Safety and pricing approval under South Korea’s National Health Insurance system. Sales are expected to contribute to revenue growth in the upcoming fiscal year through an established distribution partner.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Earlier from Nova Eye Medical
- Appendix 3Y Thomas Duthy
- Appendix 3X Dr T Duthy
- Appendix 3Z Coupe
- EYE AGM 2026 Meeting Results
- AGM 2026 Presentation
Later from Nova Eye Medical
- EYE to Present @ Bell Potter Healthcare Conference 2026
- Bell Potter Healthcare Conference Presentation
- Notification of cessation of securities - EYE
- Notification regarding unquoted securities - EYE
- Application for quotation of securities - EYE
Follow Nova Eye Medical into a list and get an email when it puts out news.
Follow Nova Eye Medical